We are joined by Othman Al-Sawaf at EHA 2019 to discuss his presentation on high efficacy of venetoclax plus obinutuzumab in patients with complex karyotype (CKT) and chronic lymphocytic leukemia (CLL): A prospective analysis from the CLL14 trial.
1. Could you tell us a little about complex karyotype (CKT) in chronic lymphocytic leukemia (CLL) and its impact on prognosis? (0:05)
2. What are the limitations of current therapeutic options for CLL CKT patients? (1:13)
3. What is the rationale for the use of venetoclax plus obinutuzumab in this treatment setting? (2:00)
4. What were the efficacy and safety findings of your recent analysis of the CLL14 trial? (3:15)
5. Which patients are most likely to respond to this combination and in which patients is it contraindicated? (4:15)
Othman Al-Sawaf has no conflicts of interest to declare in relation to this video.
Filmed at the European Hematology Association (EHA) 24th congress 2019, Amsterdam, Netherlands.
touchONCOLOGY.com is an independent information resource supporting physicians, clinicians and leading industry professionals in continuously developing their knowledge, effectiveness and productivity, via free-to-access content in multimedia formats.
Share this Video
Related Videos In Leukaemia
PART ONE: Nicholas Short, EHA 2022: Ponatinib and blinatumomab in patients with PH+ALL: Results of a phase II study
In Part One of this video interview, Prof Nicholas Short (The University of Texas MD Anderson Cancer Center, Houston, TX, USA) discusses his phase II trial looking at ponatinib and blinatumomab for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia. A total of 55 patients were treated and the combination therapy showed complete molecular response. These […]
PART TWO: Nicholas Short, EHA 2022: Ponatinib and blinatumomab in patients with PH+ALL: Results of a phase II study
In Part Two of this video interview, Prof Nicholas Short (The University of Texas MD Anderson Cancer Center, Houston, TX, USA) summaries the rationale, design and eligibility criteria of his phase II trial looking at ponatinib and blinatumomab for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia, and summarizes the key take-home conclusions. A total of […]
Jorge Cortes, EHA 2022: Magrolimab plus azacitidine in the patients with AML and HR MDS
Professor Jorge Cortes (Georgia Cancer Center, Augusta, GA, USA) summarizes two more important abstracts from the 27th Congress of the European Hematology Association (EHA) looking at magrolimab, an antibody blocking CD47, “don’t eat me” signal on cancer cells. The first is a phase III trial (NCT05079230) assessing magrolimab in combination with venetoclax and azacitidine in […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!